In CRC, circMYH9 drives tumor progression by binding hnRNPA2B1 to destabilize p53 mRNA, which alleviates p53-mediated suppression of phosphoglycerate dehydrogenase (PHGDH) and subsequently activates serine/glycine (SG) metabolic flux [205]. The gene discussed is TP53; the disease is neoplasm.